Hosted on MSN24d
Intra-Cellular price target raised to $118 from $100 at BofA
BofA raised the firm’s price target on Intra-Cellular (ITCI) to $118 from $100 and keeps a Buy rating on the shares after the company announced a favorable Caplyta patent settlement with Sandoz ...
Canaccord cuts Intra-Cellular stock rating, raises target to $132
Canaccord Genuity analysts downgraded Intra-Cellular Therapies (NASDAQ:ITCI) stock from Buy to Hold, adjusting the price target to $132 from the previous $119. The revision follows the recent ...
ETF Daily News2d
Intra-Cellular Therapies (NASDAQ:ITCI) Now Covered by StockNews.com
Cantor Fitzgerald upgraded Intra-Cellular Therapies from a “hold ... rating of “Moderate Buy” and a consensus price target of $103.62. 10 Stocks to Sell NOW! 3 Stocks to DOUBLE This ...
Johnson & Johnson Acquires Intra-Cellular in $14.6 Billion Deal
Intra-Cellular Therapies makes Caplyta, a once-daily pill for adults with schizophrenia and bipolar-related depression ...
Intra-Cellular downgraded to Hold from Buy at Canaccord
Canaccord downgraded Intra-Cellular (ITCI) to Hold from Buy with a price target of $132, up from $119, after Johnson & Johnson (JNJ) agreed ...
Intra-Cellular Therapies (NASDAQ:ITCI) Coverage Initiated at StockNews.com
Investment analysts at StockNews.com assumed coverage on shares of Intra-Cellular Therapies (NASDAQ:ITCI – Get Free Report) ...
U.S. News & World Report23d
J&J Buys Intra-Cellular in $14.6 Billion Deal, Delving Further Into Central Nervous System Disorders
Intra-Cellular said last fall it was expanding its sales force to target growth opportunities with primary care doctors. The company also is seeking U.S. Food and Drug Administration approval to ...